

Jing Zeng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1143619/publications.pdf>

Version: 2024-02-01

61
papers

1,061
citations

489802

18
h-index

511568

30
g-index

62
all docs

62
docs citations

62
times ranked

1631
citing authors

#	ARTICLE	IF	CITATIONS
1	A Prospective Study of a Resorbable Intravesical Fiducial Marker for Bladder Cancer Radiation Therapy. <i>Advances in Radiation Oncology</i> , 2022, 7, 100858.	0.6	3
2	Multitask Learning Radiomics on Longitudinal Imaging to Predict Survival Outcomes following Risk-Adaptive Chemoradiation for Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 1228.	1.7	20
3	PSMA PET: Enabling More Dose to Less Volume?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 255.	0.4	0
4	Consensus Statement on Proton Therapy in Mesothelioma. <i>Practical Radiation Oncology</i> , 2021, 11, 119-133.	1.1	11
5	Treatment Intensification in Locally Advanced/Unresectable NSCLC Through Combined Modality Treatment and Precision Dose Escalation. <i>Seminars in Radiation Oncology</i> , 2021, 31, 105-111.	1.0	3
6	Radiation and Modulation of the Tumor Immune Microenvironment in Non-Small Cell Lung Cancer. <i>Seminars in Radiation Oncology</i> , 2021, 31, 133-139.	1.0	6
7	Radiation Treatment of Non-Small Cell Lung Cancer. <i>Seminars in Radiation Oncology</i> , 2021, 31, 95-96.	1.0	0
8	Tumor control probability in hypofractionated radiotherapy as a function of total and hypoxic tumor volumes. <i>Physics in Medicine and Biology</i> , 2021, 66, 125010.	1.6	2
9	Reliability of Quantitative 18F-FDG PET/CT Imaging Biomarkers for Classifying Early Response to Chemoradiotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer. <i>Clinical Nuclear Medicine</i> , 2021, 46, 861-871.	0.7	9
10	Prognostic value of early FDG PET response imaging and peripheral immunologic biomarkers: sub-study of a phase II trial of risk-adaptive chemoradiation for unresectable non-small cell lung cancer. <i>Advances in Radiation Oncology</i> , 2021, 7, 100857.	0.6	0
11	Immunotherapy and radiation therapy for gastrointestinal malignancies: hope or hype?. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 21-21.	1.5	2
12	Scanning Beam Proton Therapy versus Photon IMRT for Stage III Lung Cancer: Comparison of Dosimetry, Toxicity, and Outcomes. <i>Advances in Radiation Oncology</i> , 2020, 5, 434-443.	0.6	9
13	Rectal Hydrogel Spacer Improves Late Gastrointestinal Toxicity Compared to Rectal Balloon Immobilization After Proton Beam Radiation Therapy for Localized Prostate Cancer: A Retrospective Observational Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 635-643.	0.4	17
14	Radiation Therapy for Small Cell Lung Cancer: An ASTRO Clinical Practice Guideline. <i>Practical Radiation Oncology</i> , 2020, 10, 158-173.	1.1	111
15	Comparison of regional lung perfusion response on longitudinal MAA SPECT/CT in lung cancer patients treated with and without functional tissue-avoidance radiation therapy. <i>British Journal of Radiology</i> , 2019, 92, 20190174.	1.0	14
16	Voxel Forecast for Precision Oncology: Predicting Spatially Variant and Multiscale Cancer Therapy Response on Longitudinal Quantitative Molecular Imaging. <i>Clinical Cancer Research</i> , 2019, 25, 5027-5037.	3.2	10
17	Clinical Outcomes of Patients With Recurrent Lung Cancer Reirradiated With Proton Therapy on the Proton Collaborative Group and University of Florida Proton Therapy Institute Prospective Registry Studies. <i>Practical Radiation Oncology</i> , 2019, 9, 280-288.	1.1	31
18	An in-silico quality assurance study of contouring target volumes in thoracic tumors within a cooperative group setting. <i>Clinical and Translational Radiation Oncology</i> , 2019, 15, 83-92.	0.9	4

#	ARTICLE	IF	CITATIONS
19	Proton therapy for thymic malignancies: multi-institutional patterns-of-care and early clinical outcomes from the proton collaborative group and the university of Florida prospective registries. <i>Acta Oncol</i> ³ <i>gica</i> , 2019, 58, 1036-1040.	0.8	12
20	Bladder Cancer Multidisciplinary Clinic (BCMC) Model Influences Disease Assessment and Impacts Treatment Recommendations. <i>Bladder Cancer</i> , 2019, 5, 289-298.	0.2	7
21	Analysis of Gastrointestinal Toxicity in Patients Receiving Proton Beam Therapy for Prostate Cancer: A Single-Institution Experience. <i>Advances in Radiation Oncology</i> , 2019, 4, 70-78.	0.6	5
22	Challenge of Proving the Value of Proton Therapy in an Unselected Patient Population in the Era of Precision Oncology: The Fallacy of a One-Size-Fits-All Strategy in Radiotherapy for Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2003-2004.	0.8	4
23	Proton beam therapy and immunotherapy: an emerging partnership for immune activation in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, 180-188.	1.3	28
24	Advanced proton beam dosimetry part II: Monte Carlo vs. pencil beam-based planning for lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, 114-121.	1.3	32
25	Decision analytic modeling for the economic analysis of proton radiotherapy for non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, 122-133.	1.3	9
26	Heart Dose and Outcomes in Radiation Treatment for Esophageal Cancer. <i>Cureus</i> , 2018, 10, e2378.	0.2	10
27	Volume dependence in hypoxia-targeted dose escalation. <i>Medical Physics</i> , 2018, 45, 5325-5331.	1.6	6
28	Radiation oncology resident training in patient safety and quality improvement: a national survey of residency program directors. <i>Radiation Oncology</i> , 2018, 13, 186.	1.2	11
29	Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes. <i>Radiation Oncology</i> , 2018, 13, 179.	1.2	4
30	Utilizing simulated errors in radiotherapy plans to quantify the effectiveness of the physics plan review. <i>Medical Physics</i> , 2018, 45, 5359-5365.	1.6	7
31	Correlation of Functional Lung Heterogeneity and Dosimetry to Radiation Pneumonitis using Perfusion SPECT/CT and FDG PET/CT Imaging. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1255-1264.	0.4	17
32	Does Neutron Radiation Therapy Potentiate an Immune Response to Merkel Cell Carcinoma?. <i>International Journal of Particle Therapy</i> , 2018, 5, 183-195.	0.9	15
33	Proton therapy in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, 103-105.	1.3	0
34	A survey of residents'™ experience with patient safety and quality improvement concepts in radiation oncology. <i>Practical Radiation Oncology</i> , 2017, 7, e253-e259.	1.1	11
35	Theoretical effectiveness of cell survival in fractionated radiotherapy with hypoxia-targeted dose escalation. <i>Medical Physics</i> , 2017, 44, 1975-1982.	1.6	10
36	SBRT in five fractions. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 652-653.	0.4	0

#	ARTICLE	IF	CITATIONS
37	Framework for radiation pneumonitis risk stratification based on anatomic and perfused lung dosimetry. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 410-418.	1.0	24
38	Functional lung avoidance and response-adaptive escalation (FLARE) RT: Multimodality plan dosimetry of a precision radiation oncology strategy. <i>Medical Physics</i> , 2017, 44, 3418-3429.	1.6	55
39	Dose Escalation Optimization in Patients With Locally Advanced Non-Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2017, 3, 1365.	3.4	2
40	Are we making an impact with incident learning systems? Analysis of quality improvement interventions using total body irradiation as a model system. <i>Practical Radiation Oncology</i> , 2017, 7, 418-424.	1.1	8
41	The relationship between cardiac radiation dose and mediastinal lymph node involvement in stage III non-small cell lung cancer patients. <i>Advances in Radiation Oncology</i> , 2017, 2, 192-196.	0.6	12
42	Evaluation of near-miss and adverse events in radiation oncology using a comprehensive causal factor taxonomy. <i>Practical Radiation Oncology</i> , 2017, 7, 346-353.	1.1	24
43	Multi-Institutional Experience of Stereotactic Ablative Radiation Therapy for Stage I Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 362-371.	0.4	78
44	Proton Therapy for Malignant Pleural Mesothelioma: A Three Case Series Describing the Clinical and Dosimetric Advantages of Proton-Based Therapy. <i>Cureus</i> , 2017, 9, e1705.	0.2	10
45	Targeting safety improvements through identification of incident origination and detection in a near-miss incident learning system. <i>Medical Physics</i> , 2016, 43, 2053-2062.	1.6	22
46	The effectiveness of pretreatment physics plan review for detecting errors in radiation therapy. <i>Medical Physics</i> , 2016, 43, 5181-5187.	1.6	40
47	Mentorship Programs in Radiation Oncology Residency Training Programs: A Critical Unmet Need. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 27-30.	0.4	32
48	Influence of planning time and treatment complexity on radiation therapy errors. <i>Practical Radiation Oncology</i> , 2016, 6, 187-193.	1.1	14
49	Proton therapy posterior beam approach with pencil beam scanning for esophageal cancer. <i>Strahlentherapie Und Onkologie</i> , 2016, 192, 913-921.	1.0	25
50	Standardizing dose prescriptions: An ASTRO white paper. <i>Practical Radiation Oncology</i> , 2016, 6, e369-e381.	1.1	30
51	Overview of the Novel and Improved Pulmonary Ventilation-Perfusion Imaging Applications in the Era of SPECT/CT. <i>American Journal of Roentgenology</i> , 2016, 207, 1307-1315.	1.0	16
52	Interrater reliability of a near-miss risk index for incident learning systems in radiation oncology. <i>Practical Radiation Oncology</i> , 2016, 6, 429-435.	1.1	6
53	Sestrin2 protects the myocardium against radiation-induced damage. <i>Radiation and Environmental Biophysics</i> , 2016, 55, 195-202.	0.6	20
54	Best practices for safety improvement through high-volume institutional incident learning: lessons learned from 2 years. <i>Journal of Radiation Oncology</i> , 2016, 5, 323-333.	0.7	3

#	ARTICLE	IF	CITATIONS
55	Sodium glycididazole enhances the radiosensitivity of laryngeal cancer cells through downregulation of ATM signaling pathway. <i>Tumor Biology</i> , 2016, 37, 5869-5878.	0.8	9
56	Can emergent treatments result in more severe errors?: An analysis of a large institutional near-miss incident reporting database. <i>Practical Radiation Oncology</i> , 2015, 5, 319-324.	1.1	9
57	Tumor length as a prognostic factor in esophageal cancer management. <i>Journal of Radiation Oncology</i> , 2015, 4, 71-77.	0.7	2
58	Metrics of success: Measuring impact of a departmental near-miss incident learning system. <i>Practical Radiation Oncology</i> , 2015, 5, e409-e416.	1.1	40
59	Measurable improvement in patient safety culture: A departmental experience with incident learning. <i>Practical Radiation Oncology</i> , 2015, 5, e229-e237.	1.1	42
60	Combination of stereotactic ablative body radiation with targeted therapies. <i>Lancet Oncology</i> , The, 2014, 15, e426-e434.	5.1	32
61	Immune Modulation and Stereotactic Radiation: Improving Local and Abscopal Responses. <i>BioMed Research International</i> , 2013, 2013, 1-8.	0.9	66